Touchlight Genetics

Demand for DNA is increasing in scale and complexity with the rapid advancement of DNA enabled therapeutics including cell and gene therapies and DNA vaccines. Plasmid DNA manufacturing is unable to adequately meet this demand, with its major limitations including cost, time, regulatory concern with antibiotic resistance genes, and difficulty amplifying DNA with complex secondary structures or repetitive sequences. Touchlight has developed an enzymatic means of DNA amplification that addresses all major limitations of plasmid DNA and meets the demands of the DNA revolution. Touchlight's in vitro dual enzyme process can amplify any circular template to commercial scale and quality. Our doggybone™ or dbDNA™ is a linear covalently closed, minimal DNA construct that contains no bacterial sequences. Our ambition is for dbDNA™ to underpin the development and commercialisation of the next generation of DNA products. Discover more about our technology and our business at
Company Growth (employees)
London, GB
Size (employees)
21 (est)+17%
Touchlight Genetics was founded in 2008 and is headquartered in London, GB

Touchlight Genetics Office Locations

Touchlight Genetics has an office in London
London, GB (HQ)
40 Queen Anne St

Touchlight Genetics Data and Metrics

Summary Metrics

Founding Date


Time since last funding

over 1 year
Touchlight Genetics's latest valuation is reported to be £25.7 m.

Touchlight Genetics Financial Metrics

£, GBP

Market valuation

25.7 m

Cash (31-Dec-2016)

193.3 k
  • Source: Company Filings,
£, GBPFY, 2014FY, 2015FY, 2016


1.7 m2 m193.3 k

Accounts Receivable

53.5 k

Current Assets

1.7 m2.3 m997.6 k


61.1 k127.5 k126.1 k

Total Assets

1.8 m2.4 m1.1 m

Accounts Payable

111 k142.9 k42.8 k

Current Liabilities

111 k2.4 m3 m

Total Equity

1.7 m12.2 k(1.8 m)

Financial Leverage

1.1 x197.8 x-0.6 x
Y, 2016

Financial Leverage

-0.6 x

Touchlight Genetics Company Life and Culture

You may also be interested in